Immunogenicity-unwanted immune responses to biological drugs – can we predict them?

References

• Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72:165–178.
   PubMed Web of Science ®Google Scholar
• Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108:40–47.
   PubMed Web of Science ®Google Scholar
• Bartelds G, Krieckaert C. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460–1468.
   PubMed Web of Science ®Google Scholar
• Arstikyte I, Kapleryte G, Butrimiene I, et al. Influence of immunogenicity on the efficacy of long-term treatment with TNF α blockers in rheumatoid arthritis and spondyloarthritis patients. Biomed Res Int. 2015;2015:604872.
   PubMed Web of Science ®Google Scholar
• Hoshino M, Yoshio T, Onishi S, et al. Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2012;22:532–540.
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348:601–608.
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711–715.
   PubMed Web of Science ®Google Scholar
• De Vries MK, Brouwer E, van der Horst-bruinsma IE, et al. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis. 2009;68:1787–1788.
   PubMed Web of Science ®Google Scholar
• Moussa EM, Panchal JP, Moorthy BS, et al. Immunogenicity of therapeutic protein aggregates. J Pharm Sci. 2016;105:417–430.
   PubMed Web of Science ®Google Scholar
• Ratanji KD, Derrick JP, Dearman RJ, et al. Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol. 2014;11:99–109.
   PubMed Web of Science ®Google Scholar
• Gorovits B, Wakshull E, Pillutla R, et al. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics. J Immunol Methods. 2014;408:1–12.
   PubMed Web of Science ®Google Scholar
• Hermeling S, Crommelin DJA, Schellekens H, et al. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res. 2004;21:897–903.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Matucci A, Nencini F, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 2010;65:657–661.
   PubMed Web of Science ®Google Scholar
• Krintel SB, Grunert VP, Hetland M, et al. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology. 2013;52:1245–1253.
   PubMed Web of Science ®Google Scholar
• Bender NK, Heilig CE, Dröll B, et al. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int. 2007;27:269–274.
   PubMed Web of Science ®Google Scholar
• Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011;13:R105.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Petroni G, Pratesi S, et al. Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions. Clin Exp Immunol. 2016;186(3):364–372.
   PubMed Web of Science ®Google Scholar
• Chiu HY, Chu TW, Cheng YP, et al. The Association between clinical response to ustekinumab and immunogenicity to ustekinumab and prior adalimumab. PLoS One. 2015;10(11):e0142930.
   PubMed Web of Science ®Google Scholar
• Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168:844–854.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Matucci A, Nencini F, et al. Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab. Int Arch Allergy Immunol. 2012;159:321–326.
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. New Engl J Med. 2008;358:1109–1117.
   PubMed Web of Science ®Google Scholar
• Stubenrauch K, Wessels U, Birnboeck H, et al. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther. 2010;32:1597–1609.
   PubMed Web of Science ®Google Scholar
• Vennegoor A, Rispens T, Strijbis EM, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler. 2013;19:593–600.
   PubMed Web of Science ®Google Scholar
• Liefferinckx C, Minsart C, Cremer A, et al. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance. Eur J Gastroenterol Hepatol. 2019;31(4):478–485.
   PubMed Web of Science ®Google Scholar
• Nencini F, Pratesi S, Petroni G, et al. Assays and strategies for immunogenicity assessment of biological agents. Drug Dev Res. 2014;75(Suppl 1):S4–S6.
   PubMedGoogle Scholar
• Bloem K, van Leeuwen A, Verbeek G, et al. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods. 2015;418:29–38.
   PubMed Web of Science ®Google Scholar
• Llinares-Tello F, Rosas-gómez de Salazar J, Senabre-Gallego JM, et al. Practical application of acid dissociation in monitoring patients treated with adalimumab. Rheumatol Int. 2014;34:1701–1708.
   PubMed Web of Science ®Google Scholar
• Lallemand C, Kavrochorianou N, Steenholdt C, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists. J Immunol Methods. 2011;373:229–239.
   PubMed Web of Science ®Google Scholar
• Bella Ungar B, Chowers Y, Yavzori M, et al. ABIRISK consortium. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014;63:1258–1264.
   PubMed Web of Science ®Google Scholar
• Hoxha A, Calligaro A, Tonello M, et al. The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: a prospective multicentre study. Joint Bone Spine. 2016;83:167–171.
   PubMed Web of Science ®Google Scholar
• Nencini F, Vultaggio A, Pratesi S, et al. The kinetics of antidrug antibodies, drug levels, and clinical outcomes in infliximab-exposed patients with immune-mediated disorders. J Allergy Clin Immunol Pract. 2018;6:2065–2072.e2.
   PubMed Web of Science ®Google Scholar
• Pratesi S, Nencini F, Grosso F, et al. T cell response to infliximab in exposed patients: a longitudinal analysis. Front Immunol. 2019;9:3113.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Nencini F, Pratesi S, et al. IL-10-producing infliximab-specific T cells regulate the anti-drug T cell response in exposed patients. J Immunol. 2017;199(4):1283–1289.
   PubMed Web of Science ®Google Scholar
• Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299–316.
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, et al. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. mAbs. 2010;2(3):256–265.
   PubMed Web of Science ®Google Scholar
• Radstake TRDJ, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheumatic Dis. 2009;68(11):1739–1745.
   PubMed Web of Science ®Google Scholar
• Chen D-Y, Chen Y-M, Hung W-T, et al. Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment. Ann Rheum Dis. 2015;74(12):2261–2264.
   PubMed Web of Science ®Google Scholar
• Chovel-Sella A, Karplus R, Sella T, et al. Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis. Isr Med Assoc J. 2012;14(6):390–394.
   PubMed Web of Science ®Google Scholar
• Zidi I, Bouaziz A, Mnif W, et al. Golimumab therapy of rheumatoid arthritis: an overview. Scand J Immunol. 2010;72(2):75–85.
   PubMed Web of Science ®Google Scholar
• Rath T, Baker K, Dumont JA, et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol. 2015;35(2):235–254.
   PubMed Web of Science ®Google Scholar
• So Yun L, Moon Sung K, Woo Yeup J, et al. Hyaluronic acid-based theranostic nanomedicines for targeted cancer therapy. Cancers (Basel). 2020;12:940–957.
   Web of Science ®Google Scholar
• Scott LJ. Tocilizumab: a review in rheumatoid arthritis. Drugs. 2017;77(17):1865–1879.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Choy E, Kivitz A, et al. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1078–1085.
   PubMed Web of Science ®Google Scholar
• Blair HA, Deeks ED. Abatacept: a review in rheumatoid arthritis. Drugs. 2017;77(11):1221–1233.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Pacheco-Tena C, Covarrubias A, et al. Longterm safety and efficacy of subcutaneous abatacept in patients with rheumatoid arthritis: 5-year results from a phase IIIb trial. J Rheumatol. 2018;45(8):1085–1092.
   PubMed Web of Science ®Google Scholar
• Matucci A, Nencini F, Rossi O, et al. The percentage of patients achieving complete remission of urticaria increases with repeated courses of treatment. J Allergy Clin Immunol Pract. 2019;7(1):339–340.
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34(4):632–638.
   PubMed Web of Science ®Google Scholar
• Odajima H, Ebisawa M, Nagakura T, et al. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma. Allergol Int. 2017;66(1):106–115.
   PubMed Web of Science ®Google Scholar
• Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003;112(6):1147–1154.
   PubMed Web of Science ®Google Scholar
• Schroeder JT, Bieneman AP, Chichester KL, et al. Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol. 2010;125(4):896–901.e6.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–2127.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Marín AC, Chaparro M. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta- analysis. Am J Gastroenterol. 2016;111(5):632–647.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Al-khalaf M, Brynskov J, et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2209–2217.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126(2):402–413.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. New Engl J Med. 2007 19; 357(3):239–250. DOI
   PubMed Web of Science ®Google Scholar
• Matucci A, Pratesi S, Petroni G, et al. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy. 2013;43:659–664.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50(5):1400–1411.
   PubMed Web of Science ®Google Scholar
• Ben-Bassat O, Hauenstein S, Iacono A, et al. Serum adalimumab and immunogenicity in IBD patients after 80 mg biweekly maintenance therapy. Gastroenterology. 2013;144(5):S771.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Yamamoto K, Yamanaka H, et al. THU0190 Better clinical responses seen early with the loading dose of certolizumab pegol are maintained until one year. Ann Rheum Dis. 2014;73:247.
   PubMed Web of Science ®Google Scholar
• Sieper J, Landewe R, Rudwaleit M, et al. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial. Arthritis Rheumatol. 2015;67(3):668–677.
   PubMed Web of Science ®Google Scholar
• Abe T, Takeuchi T, Miyasaka N, et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol. 2006;33(1):37–44.
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Xu Z, Frederick B, et al. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. Clin Ther. 2012;34(1):77–90.
   PubMed Web of Science ®Google Scholar
• Amano K, Matsubara T, Tanaka T, et al. Japan Abatacept Study Group.Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders. Mod Rheumatol. 2015;25(5):665–671.
   PubMed Web of Science ®Google Scholar
• Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32(5):425–440.
   PubMed Web of Science ®Google Scholar
• Bar-Yoseph H, Pressman S, Blatt A, et al. Infliximab-tumor necrosis factor complexes elicit formation of anti-drug antibodies. Gastroenterology. 2019;157(5):1338–1351.e8.
   PubMed Web of Science ®Google Scholar
• Somerfield J, Hill-Cawthorne GA, Lin A, et al. A novel strategy to reduce the immunogenicity of biological therapies. J Immunol. 2010;185:763–768.
   PubMed Web of Science ®Google Scholar
• Van Schie KA, Kruithof S, Ooijevaar-de Heer P, et al. Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies. Ann Rheum Dis. 2018;77:1471–1479.
   PubMed Web of Science ®Google Scholar
• Krishna M, Nadler SG. Immunogenicity to biotherapeutics - the role of anti-drug immune complexes. Front Immunol. 2016;2(7):21.
   Google Scholar
• Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology. 2014;53:213–222.
   PubMed Web of Science ®Google Scholar
• Hambardzumyan K, Hermanrud C, Marits P, et al. Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population. Scand J Rheumatol. 2019;48(5):362–366.
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. Arthritis Rheum. 2009;60(8):2541–2542.
   PubMed Web of Science ®Google Scholar
• Astermark J, Oldenburg J, Pavlova A, et al. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with haemophilia A. Blood. 2006 15; 107(8):3167–3172. DOI
   PubMed Web of Science ®Google Scholar
• Jawa V, Cousens LP, Awwad M, et al. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin Immunol. 2013;149:534–555.
   PubMed Web of Science ®Google Scholar
• Schaeverbeke T, Truchetet ME, Kostine M, et al. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology. 2016;55:210–220.
   PubMedGoogle Scholar
• Thomas SS, Borazan N, Barroso N, et al. Comparative Immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. a systematic review and meta-analysis. BioDrugs. 2015;29:241–258.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Durez P, Shestakova G, et al. Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. Rheumatology. 2016;55(1):49–55.
   PubMed Web of Science ®Google Scholar
• Liu M, Degner J, Davis JW, et al. Identification of HLA-DRB1 association to adalimumab immunogenicity. PLoS One. 2018;13(4):e0195325.
   PubMed Web of Science ®Google Scholar
• Billiet T, Vande Casteele N, Van Stappen T, et al. Immunogenicity to infliximab is associated with HLA-DRB1. Gut. 2015;64(8):1344–1345.
   PubMed Web of Science ®Google Scholar
• Sazonovs A, Kennedy NA, Moutsianas L, et al. HLA-DQA1*05 Carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’sDisease. Gastroenterology. 2020;158(1):189–199.
   PubMed Web of Science ®Google Scholar
• Louis E, Ghoul Z, Vermeire S, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn’s disease. Aliment Pharmacol Ther. 2004;19:511–519.
   PubMed Web of Science ®Google Scholar
• Ternant D, Berkane Z, Picon L, et al. Assessment of the influence of inflammation and FCGR3A genotype on infliximab pharmacokinetics and time to relapse in patients with Crohn’s disease. Clin Pharmacokinet. 2015;54:551–562.
   PubMed Web of Science ®Google Scholar
• Romero-Cara P, Torres-Moreno D, Pedregosa J, et al. A FCGR3A polymorphism predicts anti-drug antibodies in chronic inflammatory bowel disease patients treated with anti-TNF. Int J Med Sci. 2018;15(1):10–15.
   PubMed Web of Science ®Google Scholar
• Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum. 2005;34(S1):19–22.
   PubMedGoogle Scholar
• Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. Aaps J. 2012;14(2):296–302.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Jones RB, Burns SM, et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse and re-treatment. Arthritis Rheum. 2006;54:2970–2982.
   PubMed Web of Science ®Google Scholar
• Schioppo T, Ingegnoli F. Current perspective on rituximab in rheumatic diseases.. Drug Des Dev Ther. 2017;11:2891–2904.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Gils A, Accossato P, et al. Immunogenicity of biologics in inflammatory bowel diseases. Ther Adv Gastroenterol. 2008;11:1–13.
   Google Scholar